BIOGGIO, Switzerland--(BUSINESS WIRE)--Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced that it has appointed Phillipe Lutz as its new Chief Financial Officer.
